InsiderClue
Stocks · Health care · Pharmaceutical Preparations

EUPRAXIA PHARMACEUTICALS INC.

EPRX Clue Score36
British Columbia, Canada Fiscal year ends December CIK 0001581178
$6.68 -8.74% Close, 13 Oct 2026
Alert on the numbers Alert on insider trades
Price $6.68 +208.64% Close, 13 Oct 2026

Closing prices at the end of each trading day, from 3 Aug 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueNet income
Fiscal year 2022Net income−18.5EPS, diluted−0.96Fiscal year 2023Revenue0.0Net income−28.2EPS, diluted−1.17Fiscal year 2024Revenue0.0Net income−25.5EPS, diluted−0.76Fiscal year 2025Revenue0.0Net income−38.6EPS, diluted−1.03
FY2022FY2023FY2024FY2025
Revenue n/a 0.0 0.0 0.0
Growth
Net income −18.5 −28.2 −25.5 −38.6
Growth
EPS, diluted −0.96 −1.17 −0.76 −1.03
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2022Operating cash flow−14.4Fiscal year 2023Operating cash flow−20.7Fiscal year 2024Operating cash flow−30.0Fiscal year 2025Operating cash flow−28.6
FY2022FY2023FY2024FY2025
Operating cash flow −14.4 −20.7 −30.0 −28.6

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash and securities
Fiscal year 2022Cash and securities18.3Shareholders’ equity7.8Fiscal year 2023Cash and securities19.3Shareholders’ equity2.2Fiscal year 2024Cash and securities33.1Shareholders’ equity33.4Fiscal year 2025Cash and securities80.6Shareholders’ equity82.0
FY2022FY2023FY2024FY2025
Cash and securities 18.3 19.3 33.1 80.6
Shareholders’ equity 7.8 2.2 33.4 82.0

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−14.4 −20.7 −30.0 −28.6
Growth
Investment
9.8 −0.1 −0.1 −0.6
Financing
10.8 21.1 45.8 76.1

Capital expenditure, dividends and buybacks are shown as money out, so negative.